In RA studies, peptides containing Y at P1 of the binding site were particularly effective as inhibitors of the binding of collagen type II p261-273 epitope (a candidate autoantigen in RA) to HLA-DR1 or -DR4 proteins. This evidence concerns the gene TNFRSF10A and rheumatoid arthritis.